Drs Alexander and Urey walk through stabilizers vs silencers, pivotal trial data, and practical first line choices to help you select the right ATTR CM therapy for each patient.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-attr-cm-s1-ep6-2026a10006hh. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Disentangling Knots of Misfolded Proteins: Do We Really Know the Prognostic Implications of the Pathogenic V122I TTR Variant https://pubmed.ncbi.nlm.nih.gov/38657853/
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) https://clinicaltrials.gov/study/NCT04136171
Podden och tillhörande omslagsbild på den här sidan tillhör
Medscape. Innehållet i podden är skapat av Medscape och inte av,
eller tillsammans med, Poddtoppen.